Nasal and paranasal sinus cancers start inside the nose or adjoining sinuses. Persistent one-sided symptoms need assessment; biopsy identifies the tissue type. Confidence is high in this distinction, while treatment depends on the actual diagnosis. NHS definition.
- Persistent one-sided blockage or blood-stained discharge deserves assessment.
- These cancers differ from cancer of the nasopharynx behind the nose.
- Biopsy and imaging answer different questions about tissue and extent.
- A sinonasal location does not make every rare tumour the same carcinoma.
- Treatment planning should address vision, appearance, teeth and breathing.
Table of contents
- Evidence summary
- Nasal cavity, sinuses and distinct tumour types
- Workplace dust, smoking and HPV-related risk
- One-sided blockage, bleeding and eye or facial changes
- Nasendoscopy, biopsy and scans before treatment
- Current pathology and specialist planning
- Surgery, radiation and selected systemic care
- Vision, reconstruction and treatment safety
- Mouth health, eating and rehabilitation
- Supplements and follow-up after sinonasal treatment
- Human evidence and unassessed rare sinonasal cancers
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Exact site and histology | NCI sinonasal originals and CAP April 2026 protocol. | Reviewer research-support chain and CAP author interests; page/trial allocations unclosed. | Carcinoma is distinct from olfactory, salivary, melanocytic and hematologic tumours. |
| Symptoms and assessment | Current national NHS symptom and test pages. | Public context with contributor/study gaps; national website finance separately traced. | Persistent unilateral changes need assessment; biopsy and imaging have different roles. |
| Treatment roles | Current NHS treatment; selected ESMO diagnostic framework. | Relevant commercial author interests and underlying-study gaps, not independent product outcomes. | Specialist planning addresses tissue type, extent and function; no personal regimen. |
| Recovery and supplements | NCI supportive care and NHS urgent swallowing guidance. | Dated bodies and contributor/study allocations explicitly bounded. | Coordinate mouth care, swallowing, rehabilitation and follow-up; no supplement cure verdict. |
Nasal cavity, sinuses and distinct tumour types
The nasal cavity includes the passages inside the nose. Paranasal sinuses lie in the cheekbones, forehead and skull around it: maxillary, ethmoid, frontal and sphenoid. The nasopharynx is a neighboring throat site, not another name for the entire sinonasal region. NCI anatomy.
The April 2026 CAP carcinoma protocol includes squamous, sinonasal adenocarcinoma and neuroendocrine types. Olfactory neuroblastoma, salivary carcinoma, mucosal melanoma, sarcoma and hematologic malignancies require separate reporting frameworks. A site overview does not complete their individual treatment guides. CAP scope.
Ask the team for both the primary site and the exact histology. The phrase nasal cancer is useful for finding general information, but too broad to choose an operation or medicine. Keep a copy of the pathology report when seeking a second opinion.
Workplace dust, smoking and HPV-related risk
Risk factors include smoking, HPV and some occupational exposures, including wood, leather or textile dust and nickel compounds. The cause is not always identifiable; cancer can occur without a recognized risk factor. NHS risk context.
Some sinonasal squamous carcinomas are associated with HPV. That observation does not classify every nasal tumour as HPV-related or establish an individual prognosis. NCI dated HPV context.
Describe former as well as current work when giving a history. Ask occupational health about controlling hazardous dust and exposures. Exposure history informs assessment; it does not prove which exposure caused a particular tumour or rule out disease in someone without that history.
One-sided blockage, bleeding and eye or facial changes
Persistent one-sided obstruction, nosebleeds, blood-stained mucus or reduced smell can occur. Other changes include double vision, eye swelling, facial numbness, loose teeth or a neck lump. Other conditions can cause these symptoms; they still need assessment. NHS symptom account.
Tell the clinician which side is affected and what is changing. Mention eye symptoms, dental changes and facial sensation rather than describing everything as a sinus infection. New visual changes should be assessed promptly; do not wait for a routine cancer appointment to report them.
Severe breathing difficulty, choking, inability to speak, blue or grey lips or skin, or sudden confusion requires local emergency help. Do not drive yourself or wait to identify whether cancer, treatment or another condition is responsible. NHS emergency warning.
Nasendoscopy, biopsy and scans before treatment
A specialist may inspect the nose and throat with a camera, take a biopsy and assess neck nodes. CT or MRI can help establish tumour size and spread. Results need the combined specialist interpretation, not a home checklist. NHS assessment.
Imaging maps local extent before treatment; tissue examination confirms the diagnosis. Nasal-cavity and maxillary/ethmoid carcinoma staging is distinct from lymphoma, sarcoma and mucosal melanoma frameworks. NCI assessment boundaries.
Ask what each test is intended to resolve and how results will be communicated. Contact the service if a promised result or referral has not arrived. A biopsy delay does not tell you whether the finding is malignant, and a scan cannot independently settle every tissue distinction.
Current pathology and specialist planning
The April 2026 CAP protocol uses AJCC 8. Pathology records histology, margins, nerve involvement and nodes where applicable. CAP reporting framework.
The 2025 ESMO–EURACAN guideline calls for expert multidisciplinary assessment, with specialist pathology and selected molecular studies to define histology. Recommendations are clinical context; sponsored underlying outcomes are not cleared by society review. ESMO selected diagnostic framework.
Ask whether the tumour has had the pathology review appropriate to its rarity. Molecular testing can answer a classification question as well as a treatment question; ask which purpose applies. A named alteration does not by itself establish that a particular medicine is suitable or available.
Surgery, radiation and selected systemic care
Treatment may combine surgery, radiotherapy and chemotherapy. An operation can remove surrounding tissue and require reconstruction or a prosthesis; neck-node surgery is selected rather than automatic. The team should explain the intended benefit and effects on appearance and function. NHS treatment roles.
The NCI patient summary describes coordinated head-and-neck care, with reconstructive, dental, nutrition and rehabilitation specialists as needed. The treatment plan depends on the site, tissue type and extent. NCI coordinated care.
Clarify whether treatment aims for cure, control of recurrence or symptom relief. Ask why the proposed approach fits this histology and what alternatives are being considered. This overview makes no comparative survival claim, lists no personal regimen and does not transfer an approval for another head-and-neck site to every sinonasal tumour.
Vision, reconstruction and treatment safety
Surgery carries risks including bleeding, infection, pain, injury to nearby tissues and anaesthetic reactions. Obtain the operation-specific preparation, recovery and urgent-contact plan. Clarify who will manage a wound problem or pain that remains uncontrolled. NCI surgical safety.
Radiation effects depend on the exposed tissues. Head-and-neck treatment can cause mouth or throat problems, taste changes, skin reactions, fatigue and endocrine effects. Some persist or appear later; targeted treatment does not remove all risk. NCI radiation safety.
Ask the surgeon to explain the possible effects on the eye, nose, upper jaw and daily activities using your imaging. Discuss reconstruction before consenting to a major operation. Obtain clear instructions about contact lenses, spectacles or prosthetic devices where relevant; another patient’s recovery plan cannot determine yours.
Mouth health, eating and rehabilitation
Treatment can cause dry mouth, sores, infections, pain, dental problems and taste changes. Coordinate dental care with oncology and report pain that interferes with eating or sleep. Invasive dental care needs consideration of healing and bleeding risks; do not copy a home rinse prescription. NCI dated mouth-care context.
Coughing or choking with intake, food sticking, a wet voice after swallowing or breathlessness after meals needs urgent clinical advice. Swallowing problems can cause dehydration, weight loss or chest infection. Assessment should guide safe intake; a thickener or supplement drink is not automatically appropriate. NHS swallowing warning.
Head-and-neck rehabilitation can address speech, swallowing, neck swelling, reconstructive or prosthetic needs and psychological effects. Discuss functional problems during recovery rather than treating them as less important than tumour control. NCI rehabilitation.
Ask how altered smell, appearance or communication affects eating, work and relationships. Tell the team when daily tasks become difficult. Support can include practical help as well as clinical care; recovery goals should be made explicit.
Supplements and follow-up after sinonasal treatment
No diet trend, vitamin, herb or supplement has been proved in the NCI account reviewed here to cure cancer, slow it or prevent return. Products can change cancer-medicine effects. Show the pharmacist ingredients before adding an extract or high-dose vitamin. Treating a documented deficiency is a separate clinical question. NCI supplement boundary.
Keep a record of pathology, surgery, radiation and medicines, follow-up responsibility and symptoms to report between visits. Share it with primary and dental care. The monitoring schedule is individual; this guide copies no scan interval from an older summary. NCI follow-up planning.
Ask how surveillance for recurrence differs from care for persistent treatment effects. Obtain the team’s own instructions for any nasal hygiene, packing or prosthesis; no cleaning, irrigation or removal protocol is provided here. A planned surveillance visit is not a reason to defer a new concerning change.
Human evidence and unassessed rare sinonasal cancers
Treatment trials, supportive-care studies and screening research ask different questions. Before participation, ask about comparison care, meaningful patient outcomes, harms, costs and funders. Experimental care does not promise benefit. Animal and cell findings cannot establish safe human treatment. NCI research categories.
This article uses attributed clinical roles and diagnostic frameworks. Manufacturer-funded or supplied-product outcomes do not form an independent efficacy verdict. Unknown study finance remains unknown; an editorial board or society logo does not resolve it. The map separately identifies public budgets, pathology-service income and reviewer research support.
Detailed care for olfactory neuroblastoma, NUT carcinoma, SWI/SNF complex-deficient carcinoma, mucosal melanoma, salivary-type cancer, lymphoma and sarcoma remains unassessed here. Naming those recognized entities helps identify coverage gaps; it does not imply they share one prognosis or treatment.
Funding and source roles
Research funding at a glance
35 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NCI sinonasal professional PDQ | PDQ policy; Bonetti supplier-linked research, Truong incomplete declaration. Full page/trial payments unclosed. | United States; NCI, Bethesda, Maryland; international reviewers. | Tier 3 reviewer-linked research; incomplete interests. | C, provisional; named leads/derivation checked. Editorial review does not clear sponsored trials. |
| NCI sinonasal patient PDQ | PDQ policy; Bonetti supplier-linked research, Truong incomplete declaration. Full page/trial payments unclosed. | United States; NCI, Bethesda, Maryland; international reviewers. | Tier 3 reviewer-linked research; incomplete interests. | C, provisional; named leads/derivation checked. Editorial review does not clear sponsored trials. |
| CAP April 2026 sinonasal carcinoma protocol | CAP income; Cipriani maker-funded research participation, not personal/protocol fees. Full author/page allocations unclosed. | United States CAP; Northfield, Illinois; international contributors. | Tier 3 author-linked commercial research; incomplete chain. | C, provisional; selected current classification. Service/research interests and study gaps; no efficacy clearance. |
| ESMO–EURACAN 2025 sinonasal guideline | ESMO central funds; no external guideline funding reported. Authors disclose SunPharma, MSD, Merck, BMS and other commercial relationships. Full underlying-study allocations unclosed. | ESMO Switzerland; international author institutions. Exact current headquarters access limited in separate identity row. | Tier 3 commercial author interests. | C, provisional; actual full primary body and declarations read. Context only; no independent efficacy clearance. |
| ESMO 2023 annual report: historical finance | Printed pages 34–35: meeting, education, membership, grants and investment/other income. Named supporters include pharmaceutical firms. Finance period May 2022–April 2023; supporter period September 2022–July 2023. | ESMO European/international society; Swiss institutional status separately documented. | Tier 3 institution financial self-report. | B, provisional; actual selected original read. Historical routes, not current audited totals or guideline allocation. |
| ESMO institutional identity | Indexed own footer says Swiss-registered nonprofit; website funded by ESMO. Historical revenue routes in separate report. Complete current ledger unclosed. | Switzerland; indexed original gives Via Ginevra 4, 6900 Lugano. Direct page returned only limited navigation. | Tier 3 institutional identity; access-limited. | B, provisional; indexed primary footer, not full current institutional investigation. |
| NCI cancer surgery | Public budget and gifts; page/contributor/study payments unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 public clinical context, provisional. | B, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NHS nasal and sinus cancer: definition | National policy; contributor/study payments unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | B, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| NHS nasal and sinus cancer: symptoms | National policy; contributor/study payments unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | B, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| NHS nasal and sinus cancer: risk | National policy; contributor/study payments unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | B, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| NHS nasal and sinus cancer: assessment | National policy; contributor/study payments unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | B, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| NHS nasal and sinus cancer: treatment | National policy; contributor/study payments unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | B, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| CAP current protocol release register | CAP revenue profile; exact release-page and contributor allocations unclosed. | United States; Northfield, Illinois institution, international laboratory use. | Tier 3 society reporting and service context. | B, provisional — actual release entries read, not all protocols; identity/update source only. |
| CAP 2025 own annual report: selected financial tables | Actual selected table lists proficiency testing, accreditation, publications, membership, education, sponsorship/advertising and investments. Own reporting, not exact protocol allocation or full audited ledger. | United States; headquarters in separate contact row. | Tier 3 mixed service and institutional financial self-report. | B, provisional — actual selected finances read. Service and professional-advocacy incentives, incomplete allocations remain. |
| CAP current contact and support | Own contact identity; separate annual-report revenue profile. | United States; 325 Waukegan Road, Northfield, Illinois 60093–2750; additional Washington office. | Tier 3 institutional identity self-report. | B, provisional — actual address read; location does not close author or study-chain interests. |
| DEPEND March 6, 2025 original: protocol-author research funding | Actual original names Cipriani data interpretation/review roles and Bristol Myers Squibb/Celgene funding plus Chicago cancer-centre grant P30 CA14599. Sponsor reviewed manuscript. No other individual disclosures for Cipriani in this record; not proof of personal fees or protocol payment. | United States; University of Chicago affiliation/study setting. Complete sponsor ownership, headquarters, contracts and personal income not traced. | Tier 4 manufacturer-funded trial; excluded independent efficacy. | D for independence — direct seller funding. Participation/finance only; no trial benefit, dose or treatment-reduction claim adopted. |
| NCI head-and-neck cancer fact sheet | Public budget and gifts; page/contributor/study payments unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 public clinical context, provisional. | B, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NCI native mouth and throat side effects | Public budget and gifts; page/contributor/study payments unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 public clinical context, provisional. | C, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NCI radiation side effects | Public budget and gifts; page/contributor/study payments unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 public clinical context, provisional. | B, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NCI diets and supplements | Public budget and gifts; page/contributor/study payments unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 public clinical context, provisional. | B, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NCI follow-up medical care | Public budget and gifts; page/contributor/study payments unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 public clinical context, provisional. | B, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NCI clinical-trial explanation | Public budget and gifts; page/contributor/study payments unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 public clinical context, provisional. | B, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NHS swallowing-problem safety | National policy; contributor/study payments unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | C, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| NHS severe breathing warning | National policy; contributor/study payments unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | B, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| Andrea Bonetti current own biography and clinical-service page | Own biography identifies PDQ membership, Pederzoli clinical-trial/accreditation consultancy since 2024 and current responsibility for EORTC 2129 TREATctDNA. The site offers private oncology consultations. Exact remuneration and page allocation are not public here. | Italy; oncology biography identifies Pederzoli Hospital and former Mater Salutis, Legnago roles. Complete service/entity income and beneficial ownership unclosed. | Tier 4 private clinical-service self-report; financial identity only. | D for commercial independence — actual own body read. Useful identity evidence, but self-presentation and service-sales incentives remain; no clinical outcomes adopted. |
| EORTC and Menarini TREATctDNA announcement, October 19, 2023 | The joint announcement says Menarini and subsidiary Stemline will provide elacestrant for EORTC 2129. Bonetti’s separate current biography identifies his role in that project. Stemline is described as wholly owned by Menarini. This does not document personal fees or PDQ payments. | Belgium and Italy; announcement dateline Brussels/Florence. Complete trial contracts, assay support and supplier/manufacturing jurisdictions unclosed. | Tier 4 manufacturer-supplied trial; excluded independent efficacy. | D for independence — direct product-seller support is documented. Financial-role evidence only; no trial benefit, response, dose or medicine recommendation adopted. |
| EORTC institutional funding model | Actual own page lists institutional, corporate and private donations; study/service fees; industry-funded trials; EU grants and other restricted/unrestricted routes. It states there is no direct government subsidy. Its chart and narrative periods differ; no current complete audited ledger inferred. | Belgium; EORTC is established under Belgian law. Headquarters in the separate contact row. | Tier 3 institution with mixed commercial and noncommercial funding. | B, provisional — explicit routes improve transparency; fundraising incentives, dated components and exact project/reviewer allocation gaps remain. |
| EORTC current institutional contact | Own institutional identity source; mixed revenue routes documented separately. | Belgium; Avenue Emmanuel Mounier 83/11, 1200 Brussels. International clinical research. | Tier 3 institutional identity self-report. | B, provisional — actual address read; location does not establish independent evidence or identify all trial sites. |
| Menarini current headquarters and company registration | Own page identifies A. Menarini Industrie Farmaceutiche Riunite SRL and Florence company registration. The separate EORTC announcement establishes its product-supply route. Full beneficial ownership, trial amounts and individual remuneration not verified. | Italy; Via Sette Santi 1, 50131 Firenze, Florence. Headquarters is not the complete manufacturing chain. | Tier 4 therapeutic-product supplier self-report. | D for independence — direct seller interests; identity evidence only. Exact backers, subcontractors and financial allocations remain unclosed. |
| Minh Tam Truong ASTRO 2024 presenter disclosure | Actual page identifies Boston Medical Center/Boston University employment and no ownership/leadership interests. The compensation field contains an incomplete placeholder and is not interpreted as no compensation. Full income and PDQ payments remain unclosed. | United States; Boston, Massachusetts affiliations. Exact activity revenues and other backer jurisdictions unclosed. | Tier 3 incomplete author financial self-report. | C, provisional — actual identity and field contents read; malformed compensation disclosure prevents financial clearance. No event treatment claims adopted. |
| ASTRO 2022 head-and-neck committee disclosures | Actual three-page original lists Truong’s Boston Medical Center and Veterans Affairs roles plus American Board of Radiology travel expenses. This is scoped to the 2022 activity and previous year; other faculty’s commercial interests are not attributed to her. | United States; named Boston affiliations. Full ASTRO/ABR revenue, travel amounts and present reviewer income not traced. | Tier 3 dated activity financial self-report. | B, provisional — explicit historical disclosure assists provenance; it does not clear later compensation or assign payment to a later PDQ page. |
| NCI budget and appropriations, May 2026 | Congressional funding through HHS/NIH. Enacted appropriations and future requests differ; no disease-page amount assigned. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — actual budget process and dated body read; fiscal accountability, budget priorities and missing page allocation. |
| NCI Gift Fund and contribution routes, August 2025 | Public gifts/Gift Fund and Breast Cancer Research Stamp route separate from Congress. Named page donors and complete accepted receipts unclosed. | United States; 9000 Rockville Pike, Bethesda, Maryland; federal NCI. | Tier 3 institutional financial self-report. | B, provisional — actual contribution and headquarters text read; no named donor control or page sponsorship inferred. |
| NCI PDQ editorial boards, November 2022 | NCI support; non-government member honoraria/travel expenses. Declarations and recusal required; specific conflicts not publicly required. | United States; NCI, Bethesda, with international board contributors. | Tier 3 institutional process and payment self-report. | B, provisional — actual dated policy read; editorial independence does not clear member interests or sponsored underlying trials. |
| NHS national content policy, October 2022 | DHSC funding; policy states no advertising or corporate sponsorship. Full page/expert receipts unclosed. | United Kingdom; national NHS website. | Tier 3 financial/editorial self-report. | B, provisional — actual funding/accuracy policy read; next review due October 2025 passed. Not a provider-trust accounts profile. |
Frequently asked questions
Is nasal cancer the same as nasopharyngeal cancer? No. The primary sites differ. NCI anatomy.
Does one-sided blockage prove cancer? No. Other conditions can cause it, but persistent changes need assessment. NHS symptoms.
Can a scan replace tissue diagnosis? No. Imaging and biopsy answer different questions. NHS assessment.
Does this guide complete every rare sinonasal tumour? No. Separate pathology frameworks apply to several tumour families. CAP scope.
Sources and funding notes
NCI professional July 2024 and patient November 2024 originals were checked with derivation and named leads. Current NHS September 2025 bodies and CAP April 2026 scope were read. ESMO February 2025 selected diagnostic context and full financial declarations were read; its 2023 report remains historical, and current direct identity access was limited. No older numerical prognosis, personal dose, radiation fraction, operative protocol or sponsored efficacy is adopted. Rare histology-specific care and complete study/page allocations remain unassessed.
- NCI sinonasal professional PDQ — Selected anatomy, HPV and assessment boundaries; July 5, 2024 original.
- NCI sinonasal patient PDQ — Anatomy and coordinated care; November 8, 2024 derivation checked.
- CAP April 2026 sinonasal carcinoma protocol — Actual selected scope, contributors and AJCC 8 reporting.
- ESMO–EURACAN 2025 sinonasal guideline — Selected expert diagnosis and tissue-classification context only.
- ESMO 2023 annual report: historical finance — Selected historical income and supporter routes only.
- ESMO institutional identity — Indexed original legal footer; direct body limited.
- NCI cancer surgery — Selected operative safety.
- NHS nasal and sinus cancer: definition — Selected clinical context; no numerical protocol.
- NHS nasal and sinus cancer: symptoms — Selected clinical context; no numerical protocol.
- NHS nasal and sinus cancer: risk — Selected clinical context; no numerical protocol.
- NHS nasal and sinus cancer: assessment — Selected clinical context; no numerical protocol.
- NHS nasal and sinus cancer: treatment — Selected clinical context; no numerical protocol.
- CAP current protocol release register — Actual dated releases and observed protocol links only.
- CAP 2025 own annual report: selected financial tables — Institutional revenue routes only.
- CAP current contact and support — Institutional headquarters only.
- DEPEND March 6, 2025 original: protocol-author research funding — Financial-only provenance for Nicole Cipriani; clinical trial outcomes excluded.
- NCI head-and-neck cancer fact sheet — Anatomy, risk and rehabilitation context; no quantitative outcomes.
- NCI native mouth and throat side effects — Dental coordination and functional problems only; dated, no home rinse or intake protocol.
- NCI radiation side effects — Treatment-field and late-effect context.
- NCI diets and supplements — Unproved cure and treatment-compatibility boundaries.
- NCI follow-up medical care — Individual survivorship planning.
- NCI clinical-trial explanation — Human research categories and informed questions, not treatment benefit.
- NHS swallowing-problem safety — Selected urgent warning only; no diagnostic self-test or numerical protocol.
- NHS severe breathing warning — Selected urgent warning only; no diagnostic self-test or numerical protocol.
- Andrea Bonetti current own biography and clinical-service page — Reviewer identity, clinical employment and named research role only.
- EORTC and Menarini TREATctDNA announcement, October 19, 2023 — Dated trial drug-supply provenance only; breast-cancer treatment outcomes not used.
- EORTC institutional funding model — Research-organisation revenue routes only.
- EORTC current institutional contact — Research-organisation headquarters only.
- Menarini current headquarters and company registration — Named drug-provider corporate identity only.
- Minh Tam Truong ASTRO 2024 presenter disclosure — Dated reviewer identity and activity-specific declaration only.
- ASTRO 2022 head-and-neck committee disclosures — Historical, activity-specific Truong financial declaration only.
- NCI budget and appropriations, May 2026 — Institutional appropriation route only.
- NCI Gift Fund and contribution routes, August 2025 — Separate gift route and office identity; no clinical evidence.
- NCI PDQ editorial boards, November 2022 — Board independence, honoraria and conflict-disclosure scope.
- NHS national content policy, October 2022 — Website funding and editorial safeguards only.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.